Company Overview of Polaris Pharmaceuticals, Inc.
Polaris Pharmaceuticals, Inc. engages in research and development of protein drugs to treat cancer. The company was founded in 2006 and is based in San Diego, California.
9373 Towne Centre Drive
San Diego, CA 92121
Founded in 2006
Key Executives for Polaris Pharmaceuticals, Inc.
Chief Executive Officer and President
Co-Founder and Vice President of Medical Affairs
Compensation as of Fiscal Year 2013.
Polaris Pharmaceuticals, Inc. Key Developments
Polaris Group Announces the ADI-PEG 20
Jan 27 14
Polaris Group announced that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic cancer both in tissue culture and in mice with human pancreatic cancer. The company is conducting clinical trials on ADI-PEG 20 for the treatment of multiple indications, including metastatic melanoma, prostate cancer, and hepatocellular carcinoma. These results suggest that ADI-PEG 20 either alone or in combination with another radiosensitizer may potentially be of benefit in treating locally advanced pancreatic cancer. ADI-PEG 20 has a novel mechanism of action and well documented tolerability that believe makes ADI-PEG 20 an ideal candidate both as monotherapy and in combination with other agents, including cytotoxics.
Polaris Group Files New Investigational New Drug Application for ADI-PEG 20 in Leukemia
Dec 2 13
Polaris Group announced that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia. The FDA has reviewed this application, waived the 30-day review period and allowed treatment to begin. Polaris Group has previously filed other INDs under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple other indications, including metastatic melanoma, prostate cancer, and hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.
Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Nov 6 13
Polaris Group announced that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia. Polaris Group is conducting clinical trials on ADI-PEG 20 for the treatment of several other indications, including hepatocellular carcinoma. The latter indication is already in a global Phase 3 study. ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|